Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019August 16, 2022 Alterity Therapeutics

Notice of General Meeting 2019

2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

ANA NLP Poster

October 17, 2016August 16, 2022

Annual Report Filed on Form 20-F with SEC

September 7, 2017August 16, 2022

Prana to Present at the UBS Australian Healthcare Conference in Sydney and the Australian Life Science Investment Showcase in New York

July 17, 2013August 16, 2022

Recent Posts

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065